It delivers clarity on both care and medication access, which Delilah lacks
Full results aren't available yet, but Novo Nordisk said there was a "statistically significant" 0.83% reduction in A1c levels with semaglutide compared to placebo at that time point
Another major safety concern involves dosing errors, especially with compounded medications
If you think about a patient who has diabetes, hypertension, fatty liver disease or kidney disease, that patient may seek care from three or four specialists who usually work in silos in their own areas, says Sergiu Darabant, M.D., a medical cardiologist Miami Cardiac & Vascular Institute
We've flagged 0 risks for DexCom
This latest approval for Wegovy simply allows doctors to formally expand treatment to a larger group of people: those with overweight or obesity who have cardiovascular disease but not diabetes